99 results about "Live vector vaccine" patented technology

The invention relates to a multivalent Clostridium difficile vaccine comprising a Salmonella Typhi live vector comprising the cell binding domain of TcdA toxin (CBD/A) of Clostridium difficile or an antigenic fragment thereof and the cell binding domain of TcdB toxin (CBD/B) of Clostridium difficile or an antigenic fragment thereof and optionally the cell-binding subunit component (CdtB) of binary toxin of Clostridium difficile or an antigenic fragment thereof. The invention further provides methods of inducing an immune response and methods of preventing recurrence of C. difficile infections in subjects.

The present invention relates to novel plasmid constructs useful for the delivery of DNA vaccines. The present invention provides novel plasmids having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The present invention, however, is particularly useful for inducing in a patient an immune response against pathogenic viruses such as HIV, measles or influenza. Immunodeficiency virus vaccine inserts of the present invention express non-infectious HIV virus-like particles (VLP) bearing multiple viral epitopes. VLPs allow presentation of the epitopes to multiple histocompatability types, thereby reducing the possibility of the targeted virus escaping the immune response. Also described are methods for immunizing a patient by delivery of a novel plasmid of the present invention to the patient for expression of the vaccine insert therein. Optionally, the immunization protocol may include a booster vaccination that may be a live vector vaccine such as a recombinant pox virus or modified vaccinia Arbora vector. The booster live vaccine vector includes a transcription cassette expressing the same vaccine insert as the primary immunizing vector.

The present invention relates to novel plasmid constructs useful for the delivery of DNA vaccines. The present invention provides novel plasmids having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The present invention, however, is particularly useful for inducing in a patient an immune response against pathogenic viruses such as HIV, measles or influenza. Immunodeficiency virus vaccine inserts of the present invention express non-infectious HIV virus-like particles (VLP) bearing multiple viral epitopes. VLPs allow presentation of the epitopes to multiple histocompatability types, thereby reducing the possibility of the targeted virus escaping the immune response. Also described are methods for immunizing a patient by delivery of a novel plasmid of the present invention to the patient for expression of the vaccine insert therein. Optionally, the immunization protocol may include a booster vaccination that may be a live vector vaccine such as a recombinant pox virus or modified vaccinia Arbora vector. The booster live vaccine vector includes a transcription cassette expressing the same vaccine insert as the primary immunizing vector.

The invention provides a preparation method of avian influenza virus HA gene recombinant adenovirus, which creatively comprises the following steps: carrying out a series of intermediate processes on plasmid pCAGGS, adenovirus shuttle plasmid pShuttle, adenovirus framework plasmid pAdEasy-1 and the like to obtain a gene expression plasmid and other intermediate products, and transfecting the obtained recombinant adenovirus plasmid with 293 cell; and carrying out immunohistochemical screening on the recombinant virus according to the adenovirus-infected cytopathy and specific cells. By using the CAG as the promoter to express the target gene, the method obviously enhances the expression level of the target gene. The hemagglutinin recombinant adenovirus for respectively expressing H5N1 and H9N2 subtype avian influenza viruses provides a virus model for development of the H5/H9 subtype avian influenza virus bivalent nucleic acid vaccine, and also lays the foundation for development of the AIV (avian influenza virus) adenovirus live vector vaccine.

The invention discloses a Marek's disease virus (MDV) infectivity recombinant cloning system, and a construction method and application thereof and belongs to the field of biotechnologies. The MDV infectivity recombinant cloning system comprises a plurality of cosmids, wherein an MDV vaccine strain gene segment is cloned in each cosmid; the MDV vaccine strain gene segment contains mutually superposed regions and can be spliced to cover an integral MDV vaccine strain genome; an exogenous gene is inserted into a non-essential region for replication of at least one of the cosmids. The MDV infectivity recombinant cloning system can quickly and efficiently clone an exogenous gene expression cassette into the MDV genome to further realize rescue of the recombinant MDV. The recombinant cloning system can be used for very conveniently inserting different foreign genes into the corresponding regions so as to construct an MDV living-vector multi-vaccine.

The invention discloses an application of an immune attacking protection component for an inactivated ASFV (African swine fever virus) serving as a complex vaccine, and relates to an African swine fever gene engineering recombinant living vectored vaccine, subunit vaccine or nucleic acid vaccine immune attacking protection component, namely, an inactivated African swine fever virus or mixture of the inactivated African swine fever virus and adjuvants such as polysaccharides. The inactivated African swine fever virus or the mixture of the inactivated African swine fever virus and the adjuvantssuch as the polysaccharides can improve the immune attacking protection effect of an African swine fever gene engineering recombinant living vectored vaccine, a subunit vaccine or a nucleic acid vaccine, and can realize 100% protection. Besides, the invention further provides the complex vaccine jointly prepared from the immune attacking protection component and the gene engineering recombinant living vectored vaccine, the subunit vaccine or the nucleic acid vaccine.

The invention relates to a recombination newcastle disease LaSota attenuated vaccine for expressing canine distemper virus fusion protein (F) or canine distemper virus hemagglutinin protein (H). Particularly, the recombination newcastle disease LaSota attenuated vaccine is rLa-CDVR-F or rLa-CDVR-H. The invention further discloses a method for preparing the recombination newcastle disease LaSota attenuated vaccine and application of the recombination newcastle disease LaSota attenuated vaccine in preparation of vaccines/kits.

The present invention discloses a recombinant canine adenovirus-2 transfer vector, a method for constructing the recombinant canine adenovirus-2 transfer vector and an applications thereof. The recombinant canine adenovirus-2 transfer vector loses the 1412bp fragment of the E3 region, a large fragment of exogenous gene can be inserted, and moreover, a hCMV IE promoter, a multiple cloning site, an enhanced green fluorescent protein gene and a SV40 early transcribed Poly A signal sequence can be inserted in the position of the lost fragment of the E3 region. The method successfully constructs the lost recombinant CAV-2 transfer vector of the E3 region, obtains a purified canine adenovirus-2 strain containing EGFP reporter gene and optimizes the cloning and purification method thereof, an evaluation indicates that the biological property of the recombinant virus is stable, and therefore the present invention provides a technical platform for the further development of CAV-2 live vector vaccine and related fundamental researches.

The invention provides a method for constructing pseudorabies virus replication non-essential gene insertion mutation by utilizing a CRISPR/Cas9 gene editing system and obtaining a recombinant pseudorabies virus expressing a foreign gene. After the CRISPR/Cas9 gene editing system is introduced into a cell, a viral genome is identified through a pre-screened target sequence, and a pseudorabies virus gene infecting the cell is edited and recombined. The recombinant pseudorabies virus constructed by the method is inserted into a target foreign gene at a specific gene part without affecting replication of the virus, and the recombinant virus is screened forwards or backwards by utilizing a marker in the construction process, so that the obtaining efficiency of the recombinant virus is remarkably improved, and a foundation is laid for constructing a recombinant pseudorabies virus vaccine expressing the foreign gene. The method for constructing the recombinant pseudorabies virus based on theCRISPR/Cas9 gene editing system can be used for quickly constructing a recombinant virus live vector vaccine and has important application value.

The invention belongs to the technical field of biology, and mainly relates to a recombinant fowlpox virus transfer vector expressing a duck adenovirus serotype-2 (DADV2) fiber2 gene, a constructing method thereof and applications of the transfer vector. According to the transfer vector, a DADV2 fiber2 gene promoted by a fowlpox-virus-containing early-late promoter LP2EP2, a lacz gene promoted by a P11 promoter, and fowlpox virus genome replicated non-essential fragments which are LTYB and RTYB used for homologous recombination are inserted in a TA cloning site of a pMD19T-Simple vector. The method includes constructing a plasmid pMD-TYB; constructing a plasmid pMD22; constructing a plasmid pMD22-lacz; constructing an intermediate vector pMD22-TYB-lacz; constructing the transfer vector pMD22-TYB-lacz-DFB2; and subjecting the transfer vector pMD22-TYB-lacz-DFB2 to effect verification. The recombinant fowlpox virus transfer vector constructed by the method lays a foundation for development of an efficient recombinant fowlpox virus genetic engineering living-vector vaccine expressing the duck adenovirus serotype-2.

The invention discloses a genetically engineered bacteria strain expressing a porcine transmissible gastroenteritis virus. The strain is Lactococcus lactis MG1363/pMG36e-S preserved in China center for type culture collection, with a preservation number of CCTCC M 2012355. Lactococcus lactis is a common bacteria in intestinal tracts of human and majority of animals, has characteristics of bacterial resistance and diarrhoea resistance, and can be widely used for researches of viable cell oral vaccines. The recombinant Lactococcus lactis MG1363/pMG36e-S constructed in the invention can stably and reliably express S protein of active TGEV, can be used for producing genetically engineering subunit vaccines and genetically engineered live vector vaccines, provides a new method for preventing TGE, and is relatively low in cost.

The invention discloses a preparation method for expressing the duck Tembusu virus (DTMUV) prm and the E protein recombinant Newcastle disease virus (NDV). The preparation method comprises the following steps: 1) constructing full-length plasmids of an attenuated ND GM strain; 2) constructing plasmids for expressing the DTMUV prm and the E protein recombinant NDV; 3) rescuing and identifying the recombinant virus aGM-prm/E. The invention also discloses the virus aGM-prm/E prepared by the method. The virus aGM-prm/E is collected at the China Center for Type Culture Collection (CCTCC), with collection number of CCTCC V201644. A vaccine prepared by utilizing the virus can prevent the ND and the DTMUV disease and conduce to reducing virus removal after virulent NDV infection.